New research from the U-M School of Public Health shows that the American government’s early investment in COVID-19 vaccine development more than paid for itself. In just one year, national funding for testing, procurement, and distribution enabled 66 million American adults to receive at least one dose of a COVID-19 vaccine at no cost. Now, five years after the first clinical trial, an evaluation of the 2021 vaccine rollout confirms it was a strong return on investment. Read more about the findings in this research spotlight from Michigan News.
